...
首页> 外文期刊>Human gene therapy >Human Telomerase Reverse TranscriptasePromoter-Driven Oncolytic Adenovirus with E1B-19 kDa and E1B-55 kDa Gene Deletions
【24h】

Human Telomerase Reverse TranscriptasePromoter-Driven Oncolytic Adenovirus with E1B-19 kDa and E1B-55 kDa Gene Deletions

机译:人端粒酶逆转转录酶新蛋白腺瘤,具有E1B-19 KDA和E1B-55 KDA基因缺失

获取原文
获取原文并翻译 | 示例
           

摘要

We constructed an oncolytic adenovirus, Adeno-hTERT-E1A, with deletions of the viral E1B, E3A, and E3B regions and insertion of a human telomerase reverse transcriptase (hTERT) promoter-driven early viral 1A (E1A) cassette that confers high transcriptional activity in multiple human tumor cell lines. The oncolytic potential of Adeno-hTERT-ElA was characterized in comparison with that of the ElB-55kDa- and E3B-region-deleted oncolytic adenovirus ONYX-015. Tumor cells infected with Adeno-hTERT-E1A expressed dramatically higher levels of E1A oncoprotein, underwent enhanced lysis, and displayed an earlier and higher apoptotic index than cells infected with ONYX-015. Despite the increase in virus-induced apoptotic death, Adeno-hTERT-ElA replicated and produced functional progeny leading to viral spread, but with reduced efficiency compared with ONYX-015, in particular in A549 cells. Virus-induced E1A expression, host cell apoptosis, viral hexon protein production, and DNA synthesis were markedly reduced in primary human hepatocytes after infection with Adeno-hTERT-ElA as compared with ONYX-015. The strong oncolytic activity of Adeno-hTERT-ElA in tumor cell culture translated into superior antitumor activity in vivo in an MDA-MB-231 solid tumor xenograft model. Adeno-hTERT-ElA thus has strong therapeutic potential and an improved safety profile compared with ONYX-015, which may lead to reduced toxicity in the clinic.
机译:我们构建了一种葡萄糖腺病毒,腺瘤-HTERT-E1A,缺失病毒E1B,E3A和E3B区域,并插入人端粒酶逆转录酶(HTERT)启动子驱动的早期病毒1A(E1A)盒赋予高转录活性在多种人肿瘤细胞系中。与ELB-55KDA-和E3B-区域缺失的溶血性腺病毒ONYX-015相比,表征腺瘤 - HTERT-ELA的溶解潜力。肿瘤细胞感染的腺瘤-HTERT-E1A显着表达了较高水平的E1a癌蛋白,经过增强的裂解,并且呈现出比感染onyx-015的细胞更高的细胞凋亡指数。尽管病毒诱导的凋亡死亡增加,但腺瘤 - HTERT-ELA复制并产生功能性后代,导致病毒扩散,但与ONYX-015相比,效率降低,特别是在A549细胞中。病毒诱导的E1A表达,宿主细胞凋亡,病毒己酮蛋白产生和DNA合成在与腺-015相比,在腺组-HTERT-ELA相比,原发性人肝细胞在原发性人肝细胞中显着降低。肿瘤细胞培养中的腺瘤 - HTERT-ELA的强烈溶血活性转化为MDA-MB-231实体瘤异种移植模型体内体内的优质抗肿瘤活性。因此,与ONYX-015相比,Adeno-HTERT-ELA具有强大的治疗潜力和改进的安全性曲线,这可能导致临床毒性降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号